Amgen Inc. (NASDAQ:AMGN)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group LLC in a research report issued to clients and investors on Monday, July 17th. They presently have a $195.00 price objective on the medical research company’s stock. Jefferies Group LLC’s target price would suggest a potential upside of 15.09% from the company’s previous close.
Other equities analysts also recently issued research reports about the company. Oppenheimer Holdings, Inc. set a $189.00 price target on Amgen and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Mizuho set a $195.00 price target on Amgen and gave the stock a “buy” rating in a research report on Saturday, May 6th. Cowen and Company reissued a “buy” rating and set a $209.00 price target on shares of Amgen in a research report on Thursday, April 27th. Vetr downgraded Amgen from a “strong-buy” rating to a “buy” rating and set a $178.82 price target on the stock. in a research report on Monday, April 3rd. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $198.00 target price (down previously from $200.00) on shares of Amgen in a research report on Monday, May 22nd. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $186.64.
Shares of Amgen (AMGN) opened at 169.43 on Monday. Amgen has a 12-month low of $133.64 and a 12-month high of $184.21. The firm has a 50-day moving average price of $174.48 and a 200-day moving average price of $167.49. The firm has a market cap of $123.63 billion, a price-to-earnings ratio of 15.43 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.84 earnings per share. Equities research analysts anticipate that Amgen will post $12.57 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://transcriptdaily.com/2017/08/13/amgens-nasdaqamgn-buy-rating-reaffirmed-at-jefferies-group-llc-updated-updated-updated.html.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the sale, the senior vice president now directly owns 24,214 shares in the company, valued at $3,738,641.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in AMGN. Global Financial Private Capital LLC boosted its position in shares of Amgen by 21.9% in the second quarter. Global Financial Private Capital LLC now owns 12,478 shares of the medical research company’s stock worth $2,149,000 after buying an additional 2,244 shares during the last quarter. Cheviot Value Management LLC boosted its position in shares of Amgen by 4.7% in the second quarter. Cheviot Value Management LLC now owns 1,674 shares of the medical research company’s stock worth $288,000 after buying an additional 75 shares during the last quarter. Veritable L.P. boosted its position in shares of Amgen by 13.5% in the second quarter. Veritable L.P. now owns 29,522 shares of the medical research company’s stock worth $5,085,000 after buying an additional 3,508 shares during the last quarter. OxFORD Asset Management LLP boosted its position in shares of Amgen by 42.2% in the second quarter. OxFORD Asset Management LLP now owns 16,946 shares of the medical research company’s stock worth $2,919,000 after buying an additional 5,030 shares during the last quarter. Finally, Evercore Wealth Management LLC boosted its position in shares of Amgen by 13.1% in the second quarter. Evercore Wealth Management LLC now owns 14,334 shares of the medical research company’s stock worth $2,469,000 after buying an additional 1,656 shares during the last quarter. Institutional investors own 79.53% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.